Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581253 | 1.00 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL5112012 | 0.90 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL5553139 | 0.89 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL30089550 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL5878601 | 0.83 | ALDH1A1 (0.82) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL17485188 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL1662185 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL8074180 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL14692183 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL8692730 | 0.83 | CYP1A2 (0.76) | ALDH1A1HPGDKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-112142760-A | Ketanserin intermediate and preparation method of ketanserin | 江苏法安德医药科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-106866625-B | Preparation method of ketanserin | 上海鼎雅药物化学科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| CN-106866625-B | Preparation method of ketanserin | 上海鼎雅药物化学科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3174864-A2 | VMAT INHIBITORY COMPOUNDS | Oregon Health & Science University (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| EP-0089065-B1 | NOVEL PHENYLPIPERAZINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1987-06-16 | — | — | EP | disclosed |
| US-4665075-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-05-12 | — | — | US | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| EP-0184258-A2 | Novel derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
| US-4578465-A | VASODILATION AGENTS, HYPOTENSIVE AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1986-03-25 | — | — | US | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| EP-0098499-A1 | Process for preparing ketanserine | RAVIZZA S.p.A. (IT) | 1984-01-18 | — | — | EP | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| EP-0089065-A2 | Novel phenylpiperazine derivatives and process for producing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4335127-A | POTENT SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | ALDH1A1 887/4885HPGD 2224/4885KDM4E 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.